Exploration
Accueil
Racine
Exploration
Accueil

Corpus GrippeAllemagneV3

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Antiviral Medications in Seasonal and Pandemic Influenza.

Identifieur interne : 000103 ( Main/Exploration ); précédent : 000102; suivant : 000104

Antiviral Medications in Seasonal and Pandemic Influenza.

Auteurs : Regine Lehnert ; Mathias Pletz ; Annicka Reuss ; Tom Schaberg

Source :

RBID : pubmed:28043323

Descripteurs français

English descriptors

Abstract

BACKGROUND

Amantadine, oseltamivir, and zanamivir are currently available in Germany for the prevention and treatment of influenza. We review their efficacy and side-effect profiles.

METHODS

This review is based on pertinent randomized and controlled trials (RCTs) and systematic reviews retrieved by a systematic literature search, and on other relevant literature.

RESULTS

The efficacy of antiviral drugs for the prevention of symptomatic influenza ranges from 60% to 90% (number needed to treat [NNT], 8-89) depending on the population and type of drug in question. Antiviral drugs shorten the duration of illness by 0.5-1.5 days when given within 48 hours of the onset of symptoms. Neuraminidase inhibitors do not significantly lower the incidence of bronchitis in adults, or of otitis media in children; they do have a positive effect against reported, but not necessarily diagnostically confirmed pneumonia in adults (NNT, 89 [50-232]). The RCTs yielded no information about possible effects on severe cases of influenza, or on mortality, as they included only mildly or moderately ill patients, but observational studies have yielded some evidence of benefit. The most common side effects of oseltamivir (>10%) are headache, nausea, and vomiting; of zanamivir (>1%), a skin rash; and of amantadine (>1%), loss of appetite, nausea, and central nervous effects.

CONCLUSION

The benefits of antiviral drugs, particularly neuraminidase inhibitors, outweigh their risks. In deciding whether to use them, physicians should consider the properties of the currently circulating viruses and the patient's individual risk constellation, as directed in clinical treatment recommendations.


DOI: 10.3238/arztebl.2016.0799
PubMed: 28043323


Affiliations:

Links toward previous steps (curation, corpus...)

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Antiviral Medications in Seasonal and Pandemic Influenza.</title>
<author>
<name sortKey="Lehnert, Regine" sort="Lehnert, Regine" uniqKey="Lehnert R" first="Regine" last="Lehnert">Regine Lehnert</name>
<affiliation>
<nlm:affiliation>Federal Institute for Drugs and Medical Devices, Bonn; Center for Infectious Diseases and Infection Control, Jena University Hospital; Robert Koch Institute, Berlin; Agaplesion Diakoniekrankenhaus Rotenburg (Wümme).</nlm:affiliation>
<wicri:noCountry code="subField">Berlin; Agaplesion Diakoniekrankenhaus Rotenburg (Wümme)</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Pletz, Mathias" sort="Pletz, Mathias" uniqKey="Pletz M" first="Mathias" last="Pletz">Mathias Pletz</name>
</author>
<author>
<name sortKey="Reuss, Annicka" sort="Reuss, Annicka" uniqKey="Reuss A" first="Annicka" last="Reuss">Annicka Reuss</name>
</author>
<author>
<name sortKey="Schaberg, Tom" sort="Schaberg, Tom" uniqKey="Schaberg T" first="Tom" last="Schaberg">Tom Schaberg</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:28043323</idno>
<idno type="pmid">28043323</idno>
<idno type="doi">10.3238/arztebl.2016.0799</idno>
<idno type="wicri:Area/Main/Corpus">000063</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000063</idno>
<idno type="wicri:Area/Main/Curation">000063</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000063</idno>
<idno type="wicri:Area/Main/Exploration">000063</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Antiviral Medications in Seasonal and Pandemic Influenza.</title>
<author>
<name sortKey="Lehnert, Regine" sort="Lehnert, Regine" uniqKey="Lehnert R" first="Regine" last="Lehnert">Regine Lehnert</name>
<affiliation>
<nlm:affiliation>Federal Institute for Drugs and Medical Devices, Bonn; Center for Infectious Diseases and Infection Control, Jena University Hospital; Robert Koch Institute, Berlin; Agaplesion Diakoniekrankenhaus Rotenburg (Wümme).</nlm:affiliation>
<wicri:noCountry code="subField">Berlin; Agaplesion Diakoniekrankenhaus Rotenburg (Wümme)</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Pletz, Mathias" sort="Pletz, Mathias" uniqKey="Pletz M" first="Mathias" last="Pletz">Mathias Pletz</name>
</author>
<author>
<name sortKey="Reuss, Annicka" sort="Reuss, Annicka" uniqKey="Reuss A" first="Annicka" last="Reuss">Annicka Reuss</name>
</author>
<author>
<name sortKey="Schaberg, Tom" sort="Schaberg, Tom" uniqKey="Schaberg T" first="Tom" last="Schaberg">Tom Schaberg</name>
</author>
</analytic>
<series>
<title level="j">Deutsches Arzteblatt international</title>
<idno type="eISSN">1866-0452</idno>
<imprint>
<date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Antiviral Agents (therapeutic use)</term>
<term>Germany</term>
<term>Humans</term>
<term>Influenza, Human (drug therapy)</term>
<term>Neuraminidase (antagonists & inhibitors)</term>
<term>Pandemics</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Seasons</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Allemagne</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Essais contrôlés randomisés comme sujet</term>
<term>Grippe humaine (traitement médicamenteux)</term>
<term>Humains</term>
<term>Pandémies</term>
<term>Saisons</term>
<term>Sialidase (antagonistes et inhibiteurs)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en">
<term>Neuraminidase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr">
<term>Sialidase</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr">
<term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr">
<term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Germany</term>
<term>Humans</term>
<term>Pandemics</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Seasons</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Allemagne</term>
<term>Essais contrôlés randomisés comme sujet</term>
<term>Humains</term>
<term>Pandémies</term>
<term>Saisons</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<p>
<b>BACKGROUND</b>
</p>
<p>Amantadine, oseltamivir, and zanamivir are currently available in Germany for the prevention and treatment of influenza. We review their efficacy and side-effect profiles.</p>
</div>
<div type="abstract" xml:lang="en">
<p>
<b>METHODS</b>
</p>
<p>This review is based on pertinent randomized and controlled trials (RCTs) and systematic reviews retrieved by a systematic literature search, and on other relevant literature.</p>
</div>
<div type="abstract" xml:lang="en">
<p>
<b>RESULTS</b>
</p>
<p>The efficacy of antiviral drugs for the prevention of symptomatic influenza ranges from 60% to 90% (number needed to treat [NNT], 8-89) depending on the population and type of drug in question. Antiviral drugs shorten the duration of illness by 0.5-1.5 days when given within 48 hours of the onset of symptoms. Neuraminidase inhibitors do not significantly lower the incidence of bronchitis in adults, or of otitis media in children; they do have a positive effect against reported, but not necessarily diagnostically confirmed pneumonia in adults (NNT, 89 [50-232]). The RCTs yielded no information about possible effects on severe cases of influenza, or on mortality, as they included only mildly or moderately ill patients, but observational studies have yielded some evidence of benefit. The most common side effects of oseltamivir (>10%) are headache, nausea, and vomiting; of zanamivir (>1%), a skin rash; and of amantadine (>1%), loss of appetite, nausea, and central nervous effects.</p>
</div>
<div type="abstract" xml:lang="en">
<p>
<b>CONCLUSION</b>
</p>
<p>The benefits of antiviral drugs, particularly neuraminidase inhibitors, outweigh their risks. In deciding whether to use them, physicians should consider the properties of the currently circulating viruses and the patient's individual risk constellation, as directed in clinical treatment recommendations.</p>
</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
<PMID Version="1">28043323</PMID>
<DateCompleted>
<Year>2018</Year>
<Month>02</Month>
<Day>16</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>12</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1866-0452</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>113</Volume>
<Issue>47</Issue>
<PubDate>
<Year>2016</Year>
<Month>Nov</Month>
<Day>25</Day>
</PubDate>
</JournalIssue>
<Title>Deutsches Arzteblatt international</Title>
<ISOAbbreviation>Dtsch Arztebl Int</ISOAbbreviation>
</Journal>
<ArticleTitle>Antiviral Medications in Seasonal and Pandemic Influenza.</ArticleTitle>
<Pagination>
<MedlinePgn>799-807</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3238/arztebl.2016.0799</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">arztebl.2016.0799</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Amantadine, oseltamivir, and zanamivir are currently available in Germany for the prevention and treatment of influenza. We review their efficacy and side-effect profiles.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">This review is based on pertinent randomized and controlled trials (RCTs) and systematic reviews retrieved by a systematic literature search, and on other relevant literature.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The efficacy of antiviral drugs for the prevention of symptomatic influenza ranges from 60% to 90% (number needed to treat [NNT], 8-89) depending on the population and type of drug in question. Antiviral drugs shorten the duration of illness by 0.5-1.5 days when given within 48 hours of the onset of symptoms. Neuraminidase inhibitors do not significantly lower the incidence of bronchitis in adults, or of otitis media in children; they do have a positive effect against reported, but not necessarily diagnostically confirmed pneumonia in adults (NNT, 89 [50-232]). The RCTs yielded no information about possible effects on severe cases of influenza, or on mortality, as they included only mildly or moderately ill patients, but observational studies have yielded some evidence of benefit. The most common side effects of oseltamivir (>10%) are headache, nausea, and vomiting; of zanamivir (>1%), a skin rash; and of amantadine (>1%), loss of appetite, nausea, and central nervous effects.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The benefits of antiviral drugs, particularly neuraminidase inhibitors, outweigh their risks. In deciding whether to use them, physicians should consider the properties of the currently circulating viruses and the patient's individual risk constellation, as directed in clinical treatment recommendations.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lehnert</LastName>
<ForeName>Regine</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Federal Institute for Drugs and Medical Devices, Bonn; Center for Infectious Diseases and Infection Control, Jena University Hospital; Robert Koch Institute, Berlin; Agaplesion Diakoniekrankenhaus Rotenburg (Wümme).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pletz</LastName>
<ForeName>Mathias</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Reuss</LastName>
<ForeName>Annicka</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schaberg</LastName>
<ForeName>Tom</ForeName>
<Initials>T</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Dtsch Arztebl Int</MedlineTA>
<NlmUniqueID>101475967</NlmUniqueID>
<ISSNLinking>1866-0452</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.2.1.18</RegistryNumber>
<NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Dtsch Arztebl Int. 2017 Apr 14;114(15):269</RefSource>
<PMID Version="1">28468715</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>Dtsch Arztebl Int. 2017 Apr 14;114(15):269</RefSource>
<PMID Version="1">28468716</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005858" MajorTopicYN="N">Germany</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2016</Year>
<Month>01</Month>
<Day>24</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised">
<Year>2016</Year>
<Month>01</Month>
<Day>24</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2016</Year>
<Month>09</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2017</Year>
<Month>1</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2017</Year>
<Month>1</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2018</Year>
<Month>2</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">28043323</ArticleId>
<ArticleId IdType="pii">arztebl.2016.0799</ArticleId>
<ArticleId IdType="doi">10.3238/arztebl.2016.0799</ArticleId>
<ArticleId IdType="pmc">PMC5240024</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>BMJ. 2014 Apr 09;348:g2371</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24811409</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Pneumologie. 2016 Mar;70(3):151-200</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26926396</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cochrane Database Syst Rev. 2006 Apr 19;(2):CD001169</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16625539</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Health Technol Assess. 2009 Nov;13(58):1-265, iii-iv</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19954682</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cochrane Database Syst Rev. 2012 Apr 18;(4):CD002744</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22513907</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Influenza Other Respir Viruses. 2016 May;10 (3):192-204</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26602067</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cochrane Database Syst Rev. 2010 Feb 17;(2):CD001265</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20166059</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Infect Dis. 2002 Dec 1;186(11):1582-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12447733</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Infect. 2011 Jan;62(1):14-25</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20950645</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cochrane Database Syst Rev. 2012 Jan 18;1:CD008965</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22258996</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2000 May 27;355(9218):1845-50</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10866439</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Infect Dis. 2014 Feb;14(2):109-18</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24268590</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cochrane Database Syst Rev. 2014 Nov 21;(11):CD002745</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25415374</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Health Technol Assess. 2009 Feb;13(11):iii, ix-xii, 1-246</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19215705</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2015 May 2;385(9979):1729-37</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25640810</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>PLoS One. 2013;8(4):e60348</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23565231</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Antimicrob Chemother. 2003 Jan;51(1):123-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12493796</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Infect Dis. 2010 Oct 15;202(8):1154-60</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20831384</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cochrane Database Syst Rev. 2014 Apr 10;(4):CD008965</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24718923</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Infect Dis. 2011 Aug 1;53(3):277-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21677258</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Infect Dis. 2013 Feb 15;207(4):553-63</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23204175</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Emerg Infect Dis. 2009 Apr;15(4):552-60</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19331731</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Antimicrob Chemother. 2013 Mar;68(3):697-707</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23143901</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Antivir Ther. 2012;17(6):955-64</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22728756</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Intern Med. 2009 Oct 6;151(7):464-73</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19652173</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Respir Med. 2014 May;2(5):395-404</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24815805</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cochrane Database Syst Rev. 2014 Feb 10;(2):CD008139</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24515341</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2010 May 6;362(18):1708-19</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20445182</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations>
<list></list>
<tree>
<noCountry>
<name sortKey="Lehnert, Regine" sort="Lehnert, Regine" uniqKey="Lehnert R" first="Regine" last="Lehnert">Regine Lehnert</name>
<name sortKey="Pletz, Mathias" sort="Pletz, Mathias" uniqKey="Pletz M" first="Mathias" last="Pletz">Mathias Pletz</name>
<name sortKey="Reuss, Annicka" sort="Reuss, Annicka" uniqKey="Reuss A" first="Annicka" last="Reuss">Annicka Reuss</name>
<name sortKey="Schaberg, Tom" sort="Schaberg, Tom" uniqKey="Schaberg T" first="Tom" last="Schaberg">Tom Schaberg</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeAllemagneV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000103 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000103 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    GrippeAllemagneV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:28043323
   |texte=   Antiviral Medications in Seasonal and Pandemic Influenza.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:28043323" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeAllemagneV3
Wicri

This area was generated with Dilib version V0.6.35.
Data generation: Tue Jul 7 11:47:10 2020. Site generation: Sat Sep 26 09:55:33 2020